XML 178 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Long-Term Investments - Schedule of Statements of Operations (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
BioFirst [Member]    
Schedule of Statement of Operations [Line Items]    
Net sales $ 357 $ 734
Gross Profit 216 289
Net loss (770,877) (1,194,797)
Share of losses from investments accounted for using the equity method (339,171) (221,888)
Rgene [Member]    
Schedule of Statement of Operations [Line Items]    
Net sales
Gross Profit
Net loss (118,367) (1,550,123)
Share of losses from investments accounted for using the equity method